アクセス数 : ?
ダウンロード数 : ?
ID 116118
著者
板東, 浩 Tokushima University|Integrative Medicine Japan KAKEN研究者をさがす
キーワード
Inclisrian statin dyslipidemia
LDL-C
Atherosclerotic cardiovascular disease (ASCVD)
資料タイプ
学術雑誌論文
抄録
Up-to-date pharmacological topics for inclisiran and statin for dyslipidemia are described. The efficacy of inclisiran has been reported for reduction of LDL-C values. Inclisiran has been involved in gene silencing, which brings selective inhibition of a protein by targeting its mRNA. For RCTs of inclisiran, ORION 10/11 studies were conducted, where inclisiran and control groups were followed 1.5 years. LDL-C reduced in 53.8%/49.2%. RCTs of 19 meta-analyses showed whether statins will prolong life and its degree. As a result, statin can delay onset of events compared to placebo for cardiovascular death 9.3 days, myocardial infarction 18 days, and stroke 6.1 days.
掲載誌名
SunText Review of Endocrine Care
出版者
SunText Reviews
1
1
開始ページ
104
発行日
2021-06-30
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系